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Abstract 48 
This article summarises the current knowledge available on metabolism and the biological 49 
effects of n-3 docosapentaenoic acid (DPA). n-3 DPA has not been extensively studied 50 
because of the limited availability of the pure compound. n-3 DPA is an elongated metabolite 51 
of EPA and is an intermediary product between EPA and DHA. The literature on n-3 DPA is 52 
limited, however the available data suggests it has beneficial health effects. In vitro n-3 DPA 53 
is retro-converted back to EPA, however it does not appear to be readily metabolised to 54 
DHA. In vivo studies have shown limited conversion of n-3 DPA to DHA, mainly in liver, 55 
but in addition retro-conversion to EPA is evident in a number of tissues. n-3 DPA can be 56 
metabolised by lipoxygenase, in platelets, to form ll-hydroxy-7,9,13,16,19- and 14-hydroxy-57 
7,10,12,16,19-DPA. It has also been reported that n-3 DPA is effective (more so than EPA and 58 
DHA) in inhibition of aggregation in platelets obtained from rabbit blood. In addition, there is 59 
evidence that n-3 DPA possesses 10-fold greater endothelial cell migration ability than EPA, 60 
which is important in wound healing processes. An in vivo study has reported that n-3 DPA 61 
reduces the fatty acid synthase and malonyl activity levels in n-3 DPA-supplemented mice 62 
and these effects were stronger than the EPA-supplemented mice. Another recent in vivo 63 
study has reported that n-3 DPA may have a role in attenuating age related decrease in spatial 64 
learning and long term potentiation. However, more research remains to be done to further 65 
investigate the biological effects of this n-3 VLCPUFA. 66 
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Abbreviations 73 
AA, arachidonic acid; ACC, acetyl coenzyme A; ALA, alpha linolenic acid; BAE, Bovine 74 
aortic endothelial cells; ChREBP, carbohydrate response element binding protein; COX, 75 
cyclooxygenase; CPT-1, carnitine palmitoyl transferase-1; DHA, docosahexaenoic acid; 17S-76 
H(p) DPA, 17S-hydro(peroxy) docosapentaenoic acid; DPA, docosapentaenoic acid; EC, 77 
endothelial cells; EFA, essential fatty acid; EPA, eicosapentaenoic acid; FASn, fatty acid 78 
synthase; HETE, 12-hydroxy- 5,8,10,14-eicosatetraenoic acid; HNF-α, hepatic nuclear factor- 79 
α; HTT, 5,8,10-heptadecatrienoic acid; LA, linoleic acid; LOX, lipoxygenase; L-PK, liver 80 
pyruvate kinase; LT, leukotriene; LXR, liver X receptor; OHDPA, hydroxydocosapentaenoic 81 
acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, prostaglandin; PPAR, 82 
peroxisome proliferator-activated receptor; SREBP sterol regulatory element binding protein; 83 
TAG, triacylglycerol; TNF- α, tumor necrosis factor- α; TX, thromboxane; VEGF, vascular 84 
endothelial growth factor; VLCPUFA, very long chain polyunsaturated fatty acids. 85 
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1.  Introduction 98 
The realisation that brain grey matter from many different mammals was rich in n-3 long 99 
chain polyunsaturated fatty acids (n-3 VLCPUFA), especially DHA was a stimulus for much 100 
research on the biological role(s) of n-3 VLCPUFA (1, 2).  Since then many studies have 101 
been conducted to investigate the beneficial effects of n-3 VLCPUFA in neural function, 102 
reducing risk the of cardiovascular events, diabetes mellitus, inhibiting growth of tumour 103 
cells, modulating gene expression, anti-inflammatory activity and lipid lowering potential (3-104 
8). Most of these studies have been conducted on fish oils which typically contain all the 105 
three n-3 VLCPUFA, namely eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) 106 
and docosahexaenoic acid, (DHA) (Fig 1). Many studies have addressed the unique actions of 107 
EPA and DHA individually, because these two fatty acids have been available in purified 108 
form.  What has emerged from this research is that there are both unique as well as 109 
overlapping actions.  For example DHA has unique actions in promoting normal functioning 110 
of brain, while both EPA and DHA have overlapping actions in lowering blood lipid levels. 111 
Because pure n-3 DPA has not been readily available in quantity or at an affordable price, the 112 
role(s) of n-3 DPA have not been systematically examined.  To date few studies have been 113 
conducted using pure or enriched n-3 DPA, yet the data available points to beneficial effects 114 
of n-3 DPA.  The aim of this review is to summarize this current knowledge on the biological 115 
effects of n-3 DPA. 116 
 117 
2.  Synthesis and metabolism of n-3 DPA  118 
Alpha-linolenic acid (ALA) (n-3), one of the two essential fatty acids (EFA), can be 119 
metabolized in vivo by desaturation and elongation enzymes to form a series of highly 120 
unsaturated n-3 VLCPUFA. The major products of this pathway are EPA, DPA and DHA 121 
(9). n-3 DPA is formed by chain elongation of EPA which is believed to be mediated by the 122 
enzymes fatty acid elongase – 2 (FAE - 2) and FAE - 5 (10, 11). The conversion of n-3 DPA 123 
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to DHA was initially believed to be the result of the activity of Δ4 desaturase, converting 124 
7,10,13,16,19-22:5 (DPA) to 4,7,10,13,16,19-22:6 (DHA). But later studies reported that 125 
DPA was first elongated to 24:5n-3 which was then desaturated, by the activity of Δ6 126 
desaturase, to form 24:6n-3 (12). 24:6n-3 is translocated from the endoplasmic reticulum to 127 
the peroxisome where this 24 carbon fatty acid is then chain-shortened to 22:6n-3 (DHA) by 128 
β-oxidation. However, in some marine algae like Pavlova lutheri and Thraustochytrium sp., 129 
the Δ4 desaturase cDNA has been sequenced and isolated (13, 14). It has been shown that 130 
introduction of this Δ4 desaturase into Saccharomyces cerevisiae and Brassica juncea results 131 
in production of DHA in vegetative tissues (13). 132 
ALA supplementation studies conducted in 1960s, in rats, showed the increase in the tissue 133 
proportions (liver and heart) of ALA, EPA, DPA and DHA. These were long-term studies, 134 
conducted for a duration of 80-100 days, and involved refeeding rats which had initially been 135 
made EFA deficient. The results showed that supplementation with ALA there were increases 136 
in ALA, EPA, n-3 DPA and DHA as the dietary ALA level was increased (15-17). However, 137 
most human supplementation studies have led to the belief that the major products of ALA 138 
metabolism are EPA and n-3 DPA and that the capacity of humans to convert ALA to DHA 139 
is limited (18-20); tracer studies report that females have greater capacity for synthesis of 140 
DHA than males (19, 20). A recent review has summarised the data from various ALA 141 
supplementation studies conducted in human adults and concluded that ALA supplementation 142 
generally leads to an increase in plasma EPA and n-3 DPA levels but has little or no effect on 143 
DHA levels (21). In animals, ALA has been shown to be more prone to deposition in adipose 144 
tissue, β–oxidation or excretion via skin rather than metabolism to DHA (22) . An alternative 145 
reason for limited synthesis of DHA from ALA is the competition between 24:5n-3 and ALA 146 
for the Δ6 desaturase enzyme (Fig 1) (23). In other words, when there is a high ALA level, 147 
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the ALA itself (or indeed LA) could inhibit metabolism of 24:5n-3 to 24:6n-3, thus limiting 148 
the availability of the precursor to form DHA.  149 
In case of n-3 DPA, endothelial cells supplemented with DPA show a substantial increase in 150 
EPA in the cells, but there is little evidence of DHA formation. Similarly when these cells 151 
were supplemented with EPA, there was a significant increase in n-3 DPA, but not DHA (24, 152 
25). However, media from n-3 DPA-incubated cells contained small amounts of DHA 153 
suggesting that n-3 DPA was converted to DHA and then released into the media (24). In 154 
primary rat hepatocytes, it was observed that 
14
C-EPA was elongated to n-3 DPA linearly 155 
over a 24 hour period; in turn, the n-3 DPA was elongated to 24:5n-3, however no DHA was 156 
detected in these primary hepatocytes. The conversion of n-3 DPA to EPA is referred to as 157 
retro-conversion. The process of retroconversion was first described in 1970 (26) for DHA, 158 
and subsequent work in human fibroblasts indicated the retroconversion of both DHA and n-159 
3 DPA was likely to involve the peroxisomal acyl-CoA oxidase (Fig 1) (27, 28). It has been 160 
demonstrated using fibroblasts, that cells deficient in this enzyme cannot perform the chain 161 
shortening of n-3 DPA to EPA (27). 162 
Two recent in vivo studies also provide evidence for retroconversion of n-3 DPA into EPA. A 163 
study conducted in Sprague Dawley rats reported that n-3 DPA supplementation for 7 days 164 
(oral gavage of 50 mg/day of DPA as a free fatty acid) increased n-3 DPA concentrations in 165 
all tissues examined and EPA concentrations in liver, heart and skeletal muscle. However, the 166 
DHA concentration was increased only in liver (29). Similarly a study conducted in 167 
C57BL/KsJ db/db mice reported that after 4 weeks of supplementation with a synthetic 168 
triacylglycerol containing three n-3 DPA residues (tri-DPA), the proportion of EPA was 169 
increased in liver and kidney but there was no evidence of an increase in DHA in any of the 170 
tissues examined (30). There is evidence of formation of DHA from n-3 DPA in the retina of 171 
miniature poodle dogs which received an intravitreal injection of 
14
C-DPA (31). 172 
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3.  Isomers of DPA 173 
There is another isomer of DPA which is an n-6 fatty acid. The n-6 DPA content is low in 174 
most mammalian tissues, except testes tissue (32, 33). In fish & fish oils, the n-3 isomer of 175 
DPA is substantially higher than the n-6 isomer (34). An algal oil from Schizochytrium sp. 176 
which is rich in DHA, also contains about 15 % n-6 DPA (35). The physiological behaviour 177 
of n-3 and n-6 DPA differs profoundly despite only differing in the position of two double 178 
bonds in the acyl chain (36). Deficiency of n-3 fatty acids in animals leads to a depletion of 179 
DHA and a compensatory rise in n-6 DPA level in most tissues, especially brain and retina 180 
(37, 38). Supplementation with n-6 DPA did not produce the benefits afforded by DHA for 181 
spatial task performance or in other words for brain function (39). In retina, DHA is the major 182 
VLCPUFA in the rod outer segment (ROS) membrane phospholipids. In n-3 PUFA 183 
deficiency studies, the n-6 DPA does not completely replace DHA in 184 
phosphatidylethanolamine (PE) and phosphatidylcholine (PC) species in the retina and the 185 
loss of this one double bond is enough to induce functional deficits in retinal signalling 186 
pathways (40). Similarly, n-6 DPA could not fully support the protective role of DHA in cell 187 
survival and apoptosis in mouse neurobalstoma cells (41).  188 
 189 
4. Biological effects of n-3 DPA  190 
The n-3 VLCPUFA have been shown to have many beneficial biological effects. These 191 
include their role in cell membrane functions, eicosanoid production and regulation of gene 192 
expression. However, most of these studies have been conducted using either fish oil 193 
(mixture of n-3 VLCPUFA) or pure EPA and DHA. Although there are studies which suggest 194 
a positive association between dietary n-3 DPA and heart health (42, 43), there are only a 195 
limited number of studies which have investigated the biological effects of pure n-3 DPA and 196 
most of these studies have been conducted using either endothelial cells or platelets (Table 1).  197 
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A recent study reported that aged rats fed either EPA or n-3 DPA for 56 days showed 198 
neuroprotective effects (44). Both EPA and n-3 DPA attenuated the age-related increases in 199 
caspase 3 activity and microglial activation and the changes observed were associated with 200 
restoration of long term potentiation and improved performance in spatial learning task. The 201 
authors reported that both n-3 DPA and EPA reduce the age-related oxidative changes in 202 
vivo. 203 
 204 
4.1  Effect of n-3 DPA on eicosanoid production 205 
Eicosanoids are the signalling molecules in the body that control many physiological 206 
systems. Eicosanoids include prostaglandins (PG), prostacyclins, thromboxanes (TX) 207 
leukotrienes (LT), lipoxins, hydroxyeicosatetraenoic acid and epoxyeicosatetraenoic acid 208 
(45). Eicosanoid synthesis is induced in the body in different physiological and/or 209 
pathological conditions including inflammation and cancer. They are involved in modulating 210 
the intensity and duration of inflammation and immune response (46). Arachidonic acid 211 
(AA), is the substrate for the production of eicosanoids, under the action of cyclooxygenase 212 
(COX) and lipoxygenase (LOX) enzymes. In platelets, AA is metabolised by COX to form 213 
TXA2, 5,8,10 heptadecatrienoic acid (HHT) and by LOX to 12-hydroxy-5,8,10,14-214 
eicosatetraenoic acid (12-HETE) (47). In platelets, n-3 DPA is metabolized into 11- and l4-215 
hydroxy docosapentaenoic acids via the LOX pathway (47). When platelets were incubated 216 
with n-3 DPA, along with AA, this inhibited the COX enzyme thereby reducing the TXA2 217 
and HHT production from AA. In turn, more AA was available for shunting to the LOX 218 
pathway resulting in increased production of 12-HETE. 219 
Platelet aggregation is an early event in the development of thrombosis and is initiated by 220 
TXA2. The results from an ex vivo study conducted in rabbit platelets showed that EPA, n-3 221 
DPA and DHA inhibited collagen- or AA-stimulated platelet aggregation dose-dependently, 222 
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and that n-3 DPA was the most potent inhibitor (48). These fatty acids also suppressed TXA2 223 
formation by platelets which were exposed to collagen, thrombin or AA. In these 224 
experiments, n-3 DPA was the most potent inhibitor of COX-1 activity. n-3 DPA enhanced 225 
formation of 12-HETE in response to collagen or AA by intact platelets, while EPA and 226 
DHA had less of an effect. These results suggest that n-3 DPA possesses potent activity for 227 
interfering with the COX pathway and accelerating the LOX pathway, thus inhibiting platelet 228 
aggregation most effectively. In a human whole blood ex vivo study, n-3 DPA was equally 229 
effective as EPA and DHA in inhibiting platelet aggregation, in female subjects however, in 230 
male subjects only EPA inhibited platelet aggregation. (49). 231 
n-3 DPA has also been shown to reduce the prostacyclin production (by two fold) in 232 
endothelial cells (EC) compared with control cells when stimulated with endogenous AA-233 
mobilizing agents such as bradykinin and calcium ionophore A23187. It was also reported 234 
that prostacyclin production in cells incubated with EPA was less inhibited than in cells 235 
incubated with n-3 DPA. Since the inhibition was approximately proportional to the amount 236 
of EPA in cells, regardless of n-3 DPA content in the cells, this study suggested that 237 
inhibition of prostacyclin by n-3 DPA was due to its retro-conversion into EPA (50).  238 
EPA and DHA also act as precursors of novel pro-resolving and anti-inflammatory 239 
mediators. These mediators include resolvins of the E series from EPA, resolvins of the D- 240 
series or their aspirin triggered forms from DHA and LOX initiated neuroprotectins from 241 
DHA (51). These n-3 VLCPUFA-derived resolvins and protectins have unique structures, are 242 
biosynthesized by independent pathways in leukocytes, brain, microglial and retinal cells and 243 
share anti-inflammatory actions in vivo. Since n-3 DPA is known to be metabolised by LOX 244 
enzymes, it is speculated that n-3 DPA might also act as a precursor for production of DPA-245 
related D-series of resolvins or neuroprotectins. 246 
 247 
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4.2  Effect of n-3 DPA on endothelial cell (EC) migration 248 
EC migration and proliferation are important processes in the control of wound-healing 249 
response of blood vessels. Direct pretreatment of ECs with n-3 DPA (0.01-1.0 microgram/ml) 250 
resulted in a dose-dependent increase in migration in response to fetal bovine serum. 251 
Moreover, maximum stimulation of EC migration by n-3 DPA pretreatment (0.5 252 
microgram/ml) was achieved at a concentration one-tenth of that required for maximal 253 
stimulation by EPA pretreatment (5.0 micrograms/ml), indicating that n-3 DPA is a potent 254 
stimulator of EC migration. In EC, EPA was elongated to n-3 DPA, with little DHA being 255 
formed (25). These data suggest that the stimulatory effect of EPA on EC migration occurs 256 
via n-3 DPA, and that n-3 DPA may act as a powerful anti-atherogenic factor (25). Another 257 
study conducted in bovine aortic endothelial (BAE) cells reported that the migrating activity 258 
of these cells stimulated with vascular endothelial growth factor (VEGF) was suppressed by 259 
DPA pretreatment. The pretreatment of BAE cells with n-3 DPA also suppressed tube-260 
forming activity induced by VEGF, which suggests its positive role in preventing 261 
angiogenesis. The effect of n-3 DPA was stronger than those of EPA and DHA. n-3 DPA 262 
treatment of BAE cells also caused the suppression of VEGF receptor-2 (VEGFR-2, the 263 
kinase insert domain-containing receptor) expression. These data indicate that n-3 DPA has a 264 
potent inhibitory effect on angiogenesis possibly through the suppression of VEGFR-2 265 
expression (5). 266 
 267 
4.3  n-3 VLCPUFA regulate expression of several genes and enzymes 268 
One of the roles of n-3 VLCPUFA in the body is in the regulation of gene expression. 269 
Although many genes and pathways have been reported to be regulated by n-3 VLCPUFA, it 270 
is the ability of these n-3 VLCPUFA to regulate genes involved in lipid oxidation and cellular 271 
inflammation that highlights a unique molecular activity (Fig 2). A variety of mechanisms 272 
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have been proposed to account for the impact on gene expression, demonstrated both acutely 273 
and chronically, following n-3 VLCPUFA exposure, including: alterations in membrane 274 
composition and associated lipid signalling, eicosanoid production, oxidant stress, nuclear 275 
receptor activation or covalent modification of specific transcription factors (52). The 276 
discovery of Gottlicher et al (1992) of nuclear receptors capable of binding fatty acids to 277 
modulate gene expression established a direct role for fatty acids at nuclear level (53). The 278 
main receptors that interact with n-3 VLCPUFA to regulate gene expression are peroxisome 279 
proliferator receptors (PPAR), liver X receptor (LXR) and hepatic nuclear factor - 4α (HNF-280 
4α) (52). In addition, n-3 VLCPUFA also regulate gene expression by interacting with the  281 
transcription factors including; sterol regulatory element binding protein (SREBP) and 282 
carbohydrate response element binding protein (ChREBP) (54). The important lipogenic 283 
genes down-regulated by n-3 VLCPUFA are SREBP-1c, acetyl CoA carboxylase (ACC-2), 284 
fatty acid synthase (FASn) and ChREBP. SREBP-1c is a hepatic gene transcription factor 285 
that plays an important role in controlling transcription of genes involved in fatty acid 286 
synthesis, especially in liver (55).  287 
Few studies have looked at the effect of pure n-3 DPA on genes involved in fat oxidation and 288 
fat synthesis. However, in hepatocytes, n-3 DPA has been shown to induce PPARα, but EPA 289 
and DHA had a stronger and more consistent effects (56).  A recent study reported that n-3 290 
DPA reduced the expression of lipogenic genes in vivo.  Supplementation of mice with pure 291 
n-3 DPA (in TAG form) for 4 weeks significantly reduced the hepatic enzyme activity of 292 
FAS and malic enzyme (ME) in the cytosolic fraction. In this study, the mice fed with n-3 293 
DPA also showed a reduction in hepatic TG levels (30). The n-3 DPA fed to these animals 294 
was a synthetic tri-DPA which is not present naturally in the diet.  295 
n-3 DPA has also been reported to have a positive role in reducing the expression of 296 
inflammatory genes. Inflammation is an immune response to injury. However, inflammation 297 
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in walls of blood vessels is thought to play a role in the development of atherosclerotic 298 
plaques and thus lead to cardio-vascular disease. Tumor necrosis factor (TNF-α) is a 299 
prototypic pro-inflammatory cytokine and a mediator of systemic inflammation and immune 300 
responses. Supplementation of L929 murine fibrosarcoma cells with EPA, n-3 DPA and 301 
DHA was shown to reduce TNF-induced necrotic cell death; in contrast, preincubation with 302 
oleic acid, linoleic acid or 20:3n-3 did not affect TNF-induced necrosis. The order of 303 
effectiveness was DHA > n-3 DPA > / =EPA (57).  304 
 305 
4.4  Conclusions and future perspective 306 
These data suggest that n-3 DPA may possess some beneficial and perhaps unique properties, 307 
however, more extensive research is required to investigate the biological effects of pure n-3 308 
DPA in vitro and in vivo as there are still questions that remain unanswered. For example is 309 
n-3 DPA an effective precursor of DHA in brain?; is it a significant a reservoir of EPA in the 310 
body?; is n-3 DPA conserved from β-oxidation relative to other n-3 polyunsaturated fatty 311 
acids?; does n-3 DPA have any unique/specific biological properties? 312 
 313 
Acknowledgments 314 
The authors would like to acknowledge the funds provided by Meat and Livestock Australia 315 
(Project code: D.MHN.0022) and the Molecular and Medical Research Strategic Research 316 
Centre, School of Medicine, Deakin University. 317 
 318 
 319 
 320 
 321 
 322 
 323 
G. Kaur et al. 
 
-13- 
 
REFERENCES 324 
 325 
 326 
1. Crawford MA, Casperd NM, Sinclair AJ. The long chain metabolites of linoleic avid 327 
linolenic acids in liver and brain in herbivores and carnivores. Comp Biochem Physiol B. 328 
1976;54(3):395-401. 329 
2. Crawford MA, Sinclair AJ. Nutritional influences in the evolution of mammalian 330 
brain. In: lipids, malnutrition & the developing brain. Ciba Found Symp. 1971:267-92. 331 
3. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, et al. Resolvin 332 
E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects 333 
against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A. 2005 334 
May 24;102(21):7671-6. 335 
4. Aktas H, Halperin JA. Translational regulation of gene expression by omega-3 fatty 336 
acids. J Nutr. 2004 Sep;134(9):2487S-91S. 337 
5. Tsuji M, Murota SI, Morita I. Docosapentaenoic acid (22:5, n-3) suppressed tube-338 
forming activity in endothelial cells induced by vascular endothelial growth factor. 339 
Prostaglandins Leukot Essent Fatty Acids. 2003 May;68(5):337-42. 340 
6. Kitajka K, Puskas LG, Zvara A, Hackler L, Jr., Barcelo-Coblijn G, Yeo YK, et al. The 341 
role of n-3 polyunsaturated fatty acids in brain: modulation of rat brain gene expression by 342 
dietary n-3 fatty acids. Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2619-24. 343 
7. Fujikawa M, Yamazaki K, Hamazaki T, Wakaki K, Koizumi F, Yano S, et al. Effect 344 
of eicosapentaenoic acid ethyl ester on albuminuria in streptozotocin-induced diabetic rats. J 345 
Nutr Sci Vitaminol (Tokyo). 1994 Feb;40(1):49-61. 346 
8. Shimizu H, Ohtani K, Tanaka Y, Sato N, Mori M, Shimomura Y. Long-term effect of 347 
eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic 348 
patients. Diabetes Res Clin Pract. 1995 Apr;28(1):35-40. 349 
9. Mohrhauer H, Holman RT. Tracer Experiments to Assess Metabolic Conversions of 350 
Polyunsaturated Fatty Acids. J Am Oil Chem Soc. 1965 Jul;42:639-43. 351 
10. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, et al. 352 
Combined analysis of oligonucleotide microarray data from transgenic and knockout mice 353 
identifies direct SREBP target genes. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12027-354 
32. 355 
11. Wang Y, Botolin D, Christian B, Busik J, Xu J, Jump DB. Tissue-specific, nutritional, 356 
and developmental regulation of rat fatty acid elongases. J Lipid Res. 2005 Apr;46(4):706-15. 357 
12. Voss A, Reinhart M, Sankarappa S, Sprecher H. The metabolism of 7,10,13,16,19-358 
docosapentaenoic acid to 4,7,10,13,16,19-docosahexaenoic acid in rat liver is independent of 359 
a 4-desaturase. J Biol Chem. 1991 Oct 25;266(30):19995-20000. 360 
13. Qiu X, Hong H, MacKenzie SL. Identification of a Delta 4 fatty acid desaturase from 361 
Thraustochytrium sp. involved in the biosynthesis of docosahexanoic acid by heterologous 362 
expression in Saccharomyces cerevisiae and Brassica juncea. J Biol Chem. 2001 Aug 363 
24;276(34):31561-6. 364 
14. Tonon T, Harvey D, Larson TR, Graham IA. Identification of a very long chain 365 
polyunsaturated fatty acid Delta4-desaturase from the microalga Pavlova lutheri. FEBS Lett. 366 
2003 Oct 23;553(3):440-4. 367 
15. Mohrhauer H, Holman RT. Effect of Linolenic Acid Upon the Metabolism of Linoleic 368 
Acid. J Nutr. 1963 Sep;81:67-74. 369 
16. Mohrhauer H, Holman RT. The Effect of Dietary Essential Fatty Acids Upon 370 
Composition of Polyunsaturated Fatty Acids in Depot Fat and Erythrocytes of the Rat. J 371 
Lipid Res. 1963 Jul;4:346-50. 372 
G. Kaur et al. 
 
-14- 
 
17. Mohrhauer H, Holman RT. The Effect of Dose Level of Essential Fatty Acids Upon 373 
Fatty Acid Composition of the Rat Liver. J Lipid Res. 1963 Apr;4:151-9. 374 
18. Burdge GC, Calder PC. Conversion of alpha-linolenic acid to longer-chain 375 
polyunsaturated fatty acids in human adults. Reprod Nutr Dev. 2005 Sep-Oct;45(5):581-97. 376 
19. Burdge GC, Jones AE, Wootton SA. Eicosapentaenoic and docosapentaenoic acids 377 
are the principal products of alpha-linolenic acid metabolism in young men. Br J Nutr. 2002 378 
Oct;88(4):355-63. 379 
20. Burdge GC, Wootton SA. Conversion of alpha-linolenic acid to eicosapentaenoic, 380 
docosapentaenoic and docosahexaenoic acids in young women. Br J Nutr. 2002 381 
Oct;88(4):411-20. 382 
21. Brenna JT, Salem N, Jr., Sinclair AJ, Cunnane SC. alpha-Linolenic acid 383 
supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. 384 
Prostaglandins Leukot Essent Fatty Acids. 2009 Feb-Mar;80(2-3):85-91. 385 
22. Fu Z, Sinclair AJ. Novel pathway of metabolism of alpha-linolenic acid in the guinea 386 
pig. Pediatr Res. 2000 Mar;47(3):414-7. 387 
23. Portolesi R, Powell BC, Gibson RA. Competition between 24:5n-3 and ALA for 388 
{Delta}6 desaturase may limit the accumulation of DHA in HepG2 cell membranes. J Lipid 389 
Res. 2007 Jul;48(7):1592-8. 390 
24. Achard F, Benistant C, Lagarde M. Interconversions and distinct metabolic fate of 391 
eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in bovine aortic endothelial 392 
cells. Biochim Biophys Acta. 1995 Apr 6;1255(3):260-6. 393 
25. Kanayasu-Toyoda T, Morita I, Murota S. Docosapentaenoic acid (22:5, n-3), an 394 
elongation metabolite of eicosapentaenoic acid (20:5, n-3), is a potent stimulator of 395 
endothelial cell migration on pretreatment in vitro. Prostaglandins Leukot Essent Fatty Acids. 396 
1996 May;54(5):319-25. 397 
26. Stoffel W, Eker, Assad H, Sprecher H. Enzymatic studies on the mechanism of the 398 
retroconversion of C22-polyenoic fatty acids to their C20-homologues. Hoppe Seylers Z 399 
Physiol Chem. 1970 Dec;351(12):1545-54. 400 
27. Christensen E, Woldseth B, Hagve TA, Poll-The BT, Wanders RJ, Sprecher H, et al. 401 
Peroxisomal beta-oxidation of polyunsaturated long chain fatty acids in human fibroblasts. 402 
The polyunsaturated and the saturated long chain fatty acids are retroconverted by the same 403 
acyl-CoA oxidase. Scand J Clin Lab Invest Suppl. 1993;215:61-74. 404 
28. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-405 
activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr. 2001;21:193-230. 406 
29. Kaur G, Begg DP, Barr D, Garg M, Cameron-Smith D, Sinclair AJ. Short-term 407 
docosapentaenoic acid (22:5 n-3) supplementation increases tissue docosapentaenoic acid, 408 
DHA and EPA concentrations in rats. Br J Nutr.  Jan;103(1):32-7. 409 
30. Gotoh N, Nagao K, Onoda S, Shirouchi B, Furuya K, Nagai T, et al. Effects of three 410 
different highly purified n-3 series highly unsaturated fatty acids on lipid metabolism in 411 
C57BL/KsJ-db/db mice. J Agric Food Chem. 2009 Nov 25;57(22):11047-54. 412 
31. Alvarez RA, Aguirre GD, Acland GM, Anderson RE. Docosapentaenoic acid is 413 
converted to docosahexaenoic acid in the retinas of normal and prcd-affected miniature 414 
poodle dogs. Invest Ophthalmol Vis Sci. 1994 Feb;35(2):402-8. 415 
32. Tam PS, Sawada R, Cui Y, Matsumoto A, Fujiwara Y. The metabolism and 416 
distribution of docosapentaenoic acid (n-6) in the liver and testis of growing rats. Biosci 417 
Biotechnol Biochem. 2008 Oct;72(10):2548-54. 418 
33. Tam PS, Umeda-Sawada R, Yaguchi T, Akimoto K, Kiso Y, Igarashi O. The 419 
metabolism and distribution of docosapentaenoic acid (n-6) in rats and rat hepatocytes. 420 
Lipids. 2000 Jan;35(1):71-5. 421 
G. Kaur et al. 
 
-15- 
 
34. Gundstone FD, Harwood JL, Padley FB. The Lipid Handbook. London: Chapman & 422 
Hall,; 1994. 423 
35. Sanders TA, Gleason K, Griffin B, Miller GJ. Influence of an algal triacylglycerol 424 
containing docosahexaenoic acid (22 : 6n-3) and docosapentaenoic acid (22 : 5n-6) on 425 
cardiovascular risk factors in healthy men and women. Br J Nutr. 2006 Mar;95(3):525-31. 426 
36. Deng Y, Almsherqi ZA, Shui G, Wenk MR, Kohlwein SD. Docosapentaenoic acid 427 
(DPA) is a critical determinant of cubic membrane formation in amoeba Chaos mitochondria. 428 
Faseb J. 2009 Sep;23(9):2866-71. 429 
37. Guesnet P, Pascal G, Durand G. Effects of dietary alpha-linolenic acid deficiency 430 
during pregnancy and lactation on lipid fatty acid composition of liver and serum in the rat. 431 
Reprod Nutr Dev. 1988;28(2A):275-92. 432 
38. Homayoun P, Durand G, Pascal G, Bourre JM. Alteration in fatty acid composition of 433 
adult rat brain capillaries and choroid plexus induced by a diet deficient in n-3 fatty acids: 434 
slow recovery after substitution with a nondeficient diet. J Neurochem. 1988 Jul;51(1):45-8. 435 
39. Lim SY, Hoshiba J, Salem N, Jr. An extraordinary degree of structural specificity is 436 
required in neural phospholipids for optimal brain function: n-6 docosapentaenoic acid 437 
substitution for docosahexaenoic acid leads to a loss in spatial task performance. J 438 
Neurochem. 2005 Nov;95(3):848-57. 439 
40. Niu SL, Mitchell DC, Lim SY, Wen ZM, Kim HY, Salem N, Jr., et al. Reduced G 440 
protein-coupled signaling efficiency in retinal rod outer segments in response to n-3 fatty acid 441 
deficiency. J Biol Chem. 2004 Jul 23;279(30):31098-104. 442 
41. Kim HY, Akbar M, Lau A. Effects of docosapentaenoic acid on neuronal apoptosis. 443 
Lipids. 2003 Apr;38(4):453-7. 444 
42. Oda E, Hatada K, Katoh K, Kodama M, Nakamura Y, Aizawa Y. A case-control pilot 445 
study on n-3 polyunsaturated fatty acid as a negative risk factor for myocardial infarction. Int 446 
Heart J. 2005 Jul;46(4):583-91. 447 
43. Rissanen T, Voutilainen S, Nyyssonen K, Lakka TA, Salonen JT. Fish oil-derived 448 
fatty acids, docosahexaenoic acid and docosapentaenoic acid, and the risk of acute coronary 449 
events: the Kuopio ischaemic heart disease risk factor study. Circulation. 2000 Nov 450 
28;102(22):2677-9. 451 
44. Kelly L, Grehan B, Chiesa A, O’Mara S, Downer E, Sahyoun G, et al. The 452 
polyunsaturated fatty acids, EPA and DPA exert a protective effect in the hippocampus of the 453 
aged rat. Neurobiology of Aging. 2010;Article in press. 454 
45. Tassoni D, Kaur G, Weisinger R, Sinclair A. The role of eicosanoids in the brain. 455 
Asia Pac J Clin Nutr. 2008;17(S1):220-8. 456 
46. Calder PC, Grimble RF. Polyunsaturated fatty acids, inflammation and immunity. Eur 457 
J Clin Nutr. 2002 Aug;56 Suppl 3:S14-9. 458 
47. Careaga MM, Sprecher H. Synthesis of two hydroxy fatty acids from 7,10,13,16,19-459 
docosapentaenoic acid by human platelets. J Biol Chem. 1984 Dec 10;259(23):14413-7. 460 
48. Akiba S, Murata T, Kitatani K, Sato T. Involvement of lipoxygenase pathway in 461 
docosapentaenoic acid-induced inhibition of platelet aggregation. Biol Pharm Bull. 2000 462 
Nov;23(11):1293-7. 463 
49. Phang M, Garg ML, Sinclair AJ. Inhibition of platelet aggregation by omega-3 464 
polyunsaturated fatty acids is gender specific-Redefining platelet response to fish oils. 465 
Prostaglandins Leukot Essent Fatty Acids. 2009 Jul;81(1):35-40. 466 
50. Benistant C, Achard F, Ben Slama S, Lagarde M. Docosapentaenoic acid (22:5,n-3): 467 
metabolism and effect on prostacyclin production in endothelial cells. Prostaglandins Leukot 468 
Essent Fatty Acids. 1996 Oct;55(4):287-92. 469 
51. Serhan CN, Chiang N. Endogenous pro-resolving and anti-inflammatory lipid 470 
mediators: a new pharmacologic genus. Br J Pharmacol. 2007 Oct 29;153(1:S):200-15. 471 
G. Kaur et al. 
 
-16- 
 
52. Chow CK, editor. Fatty acids in foods and their health implications. Third ed. Boca 472 
Raton: CRC Press; 2008. 473 
53. Gottlicher M, Widmark E, Li Q, Gustafsson JA. Fatty acids activate a chimera of the 474 
clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci U S A. 475 
1992 May 15;89(10):4653-7. 476 
54. Chow CK. Fatty Acids in Foods andTheir Health Implications. Third, illustrated, 477 
revised ed. Chow CK, editor. Boca Raton: CRC Press; 2007. 478 
55. Horton JD, Goldstein JL, Brown MS. SREBPs: transcriptional mediators of lipid 479 
homeostasis. Cold Spring Harb Symp Quant Biol. 2002;67:491-8. 480 
56. Pawar A, Jump DB. Unsaturated fatty acid regulation of peroxisome proliferator-481 
activated receptor alpha activity in rat primary hepatocytes. J Biol Chem. 2003 Sep 482 
19;278(38):35931-9. 483 
57. Kishida E, Tajiri M, Masuzawa Y. Docosahexaenoic acid enrichment can reduce 484 
L929 cell necrosis induced by tumor necrosis factor. Biochim Biophys Acta. 2006 485 
Apr;1761(4):454-62. 486 
58. Williard DE, Harmon SD, Kaduce TL, Preuss M, Moore SA, Robbins ME, et al. 487 
Docosahexaenoic acid synthesis from n-3 polyunsaturated fatty acids in differentiated rat 488 
brain astrocytes. J Lipid Res. 2001 Sep;42(9):1368-76. 489 
59. Langelier B, Alessandri JM, Perruchot MH, Guesnet P, Lavialle M. Changes of the 490 
transcriptional and fatty acid profiles in response to n-3 fatty acids in SH-SY5Y 491 
neuroblastoma cells. Lipids. 2005 Jul;40(7):719-28. 492 
 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
 507 
 508 
 509 
 510 
 511 
 512 
 513 
 514 
 515 
 516 
 517 
 518 
 519 
 520 
 521 
G. Kaur et al. 
 
-17- 
 
LOX 
EPA (20:5n-3) 
 
DPA (22:5n-3) 
 
24:6n-3 
 
24:5n-3 
 
DHA (22:6n-3) 
 
 522 
 523 
 524 
    525 
 526 
    527 
  528 
    529 
 530 
  531 
 532 
    533 
   534 
    535 
        536 
 537 
 538 
 539 
      540 
 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
 549 
Fig 1: Metabolites of n-3 DPA. DPA forms two hydroxy acids (11- and 14-OH DPA) via an 550 
indomethacin-insensitive pathway. DPA can be retro-converted into EPA in cells and animals 551 
and is likely to involve the peroxisomal acyl coA oxidase. Since n-3 DPA is known to be 552 
metabolized by LOX enzymes, it is speculated that n-3 DPA might also act as a precursor for 553 
production of DPA-related D-series of resolvins or neuroprotectins. 554 
(Abbreviations: EPA – Eicosapentaenoic acid; DPA – Docosapentaenoic acid; DHA – 555 
Docosahexenoic acid; LOX – Lipooxygenase; OH DPA – Hydroxy docosapentaenoic acid; 17S-556 
H(p)DPA – 17S hydro (peroxy) docosapentaenoic acid.) 557 
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Fig 2 Mechanisms involved in triacylglycerol lowering effect of n-3 VLCPUFA. n-3 564 
VLCPUFA mediate the triacylglycerol lowering effect by upregulating fat oxidation genes 565 
like PPAR and CPT-1. They also downregulate the genes involved in fat synthesis like 566 
SREBP-1c, ACC and FASn, thereby decreasing the fat synthesis n-3 VLCPUFA also decrease 567 
expression of ChREBP which inturn lowers the expression of L-PK and lower the amount of 568 
carbohydrates available for triacylglycerol synthesis. (PUFA polyunsaturated fatty acids; 569 
PPAR peroxisome proliferator receptor ; CPT-1 carnitine palmitoyl transferase 1; SREBP-1c 570 
sterol regulatory element binding protein, L-PK liver pyruvate kinase, ACC acetyl CoA 571 
carboxylase; FASn fatty acid synthase; ChREBP carbohydrate response element binding 572 
protein.) 573 
 574 
 575 
 576 
 577 
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 580 
 581 
Table 1: List of literature available on n-3 DPA 582 
Year Author Model Findings 
In vitro and ex vivo Studies 
1984 Careaga and Sprecher Human platelets Platelets metabolize 7,10,13,16,19-DPA (22:5(n-3)) into ll-hydroxy-7,9,13,16,19- and 
14-hydroxy-7,10,12,16,19-DPA via an indomethacin-insensitive pathway. n-3 DPA 
inhibits the synthesis of both 5,8,10-heptadecatrienoic acid and thromboxine B2 from 
arachidonic acid. 
1991 Rosenthal et al Fibroblasts and 
retinoblasts 
Although fibroblasts desaturate [14C]22:5(n-3), the process appears to be qualitatively 
different from that of retinoblastoma cells. 
1993 Christensen et al Fibroblasts Peroxisomal acyl CoA oxidase is responsible for the chain-shortening of DHA and n-3 
DPA. 
1995 Achard et al Endothelial cells EPA, n-3 DPA and DHA are actively interconverted to each other in endothelial cells. 
1996 Benistant et al Endothelial cells n-3 DPA bound to albumin  produced two-fold less prostacyclin compared to control 
cells when stimulated with endogenous arachidonic acid-mobilizing agents 
1996 Kanayasu-Toyoda et al Endothelial cells The stimulative effect of EPA on EC migration occurs via n-3 DPA, and that n-3 DPA 
may act as a powerful anti-atherogenic factor. 
2000 Akiba et al Rabbit platelets(ex vivo) EPA, n-3 DPA and DHA inhibit collagen- or arachidonic acid-stimulated platelet 
aggregation dose-dependently among which  n-3 DPA was the most potent inhibitor. 
2001 Arita et al Human promyelocytic 
leukemia cells 
n-3 VLCPUFA including n-3 DPA-induce apoptosis of leukemia cells (HL-60), in part 
by direct action on the cells and by activation of the caspase cascade through cytochrome 
c release coupled with mitochondrial membrane depolarization. 
2001 Williard et al Rat brain astrocytes Astrocytes can synthesise and incorporate [3-
14
C]DHA into the cell PL from [3-
14
C]ALA 
and [3-
14
C]DPA and also release it into the media as free fatty acid (58). 
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2003 Tsuji et al Endothelial cells n-3 DPA suppressed tube-forming activity induced by vascular endothelial growth factor 
(VEGF) and n-3 DPA has a potent inhibitory effect on angiogenesis through the 
suppression of VEGFR-2 expression 
2003 Pawar and Jump Hepatocytes Metabolic labelling indicated that a significant fraction of 14C-EPA was elongated to n-
3 DPA in hepatocytes. Cells treated with DPA or DHA led to a significant accumulation 
of EPA in the NEFA pool. EPA and DHA, but not n-3 DPA, are active ligands for 
PPARα. 
2005 Langelier et al Neuroblastoma cells The incorporation of EPA, DPA, and preformed DHA followed a dose–response 
saturating curve, whereas that of DHA synthesized either from α-LNA, EPA, or DPA 
peaked at concentrations of precursors below 15–30 μM and sharply decreased with 
higher doses. DPA was readily formed from EPA and DHA was formed from both EPA 
and n-3 DPA (59). 
2006 Kishida et al Fibrosarcoma cells Attenuation of TNF-induced necrosis by the supplementation of various C20 or C22 
polyunsaturated fatty acids is mainly attributable to the enrichment of three kinds of 
polyunsaturated fatty acids, i.e., DHA, n-3 DPA or AA, in cell phospholipids. 
2009 Phang et al Human platelets (ex 
vivo) 
EPA was significantly more effective in reducing platelet aggregation compared with  n-
3 DPA and DHA. However, when grouped by gender, in females all three n-3VLCPUFA 
were effective. But in men EPA was more effective than  n-3 DPA and DHA. 
 
In vivo Studies 
1993 Alvarez et al Miniature poodle dogs Intravitreal injection of dogs with 
14
C-DPA (n-3) led to formation of 
14
C-DHA in the rod 
outer segment lipids. There was no difference in % dpm of DHA generated in normal 
dogs and dogs affected with progressive rod-cone degeneration. There was also evidence 
of label in 24:5 n-3 and 24:6 n-3.  
2009 Kaur et al Sprague Dawley rats n-3 DPA can be converted to DHA in the liver, in a short-term study, and that in addition 
it is partly retroconverted to EPA in liver, adipose, heart and skeletal muscle. 
2009 Gotoh et al C57BL/KsJ-db/db mice n-3 DPA and DHA treatment decreased the hepatic TG levels compared to the control 
while EPA was most effective in reducing serum TG levels. 
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 583 
(Abbreviations: EPA – Eicosapentaenoic acid; n-3 DPA – Docosapentaenoic acid; DHA – Docosahexaenoic acid; LOX – Lipooxygenase)584 
2010 Kelly et al Young and aged rats Oral doses of n-3 DPA downregulated microglial activation and decreased the activation 
of sphingomyelinase and caspase 3 and consequently attenuated the age-related decrease 
in spatial learning and long-term potentiation. 
Association Studies 
2000 Rissanen et al - Men in the highest fifth of the proportion of serum DHA +  n-3 DPA in all fatty acids 
had a 44% reduced risk of acute coronary events compared with men in the lowest fifth 
in a prospective population study. 
2005 Oda et al - Serum levels (%weight) of linolenic acid, EPA, n-3 DPA, and total n-3 VLCPUFA were 
significantly lower in patients with acute myocardial infarction than the control group in 
a case control study. 
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